{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:21:44Z","timestamp":1762867304605,"version":"build-2065373602"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":1802,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1002\/rth2.12066","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T07:53:11Z","timestamp":1513583591000},"page":"19-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Novel therapies in thrombotic thrombocytopenic purpura"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1380-3799","authenticated-orcid":false,"given":"Camila","family":"Masias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spero R.","family":"Cataland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/rth2.12066_bb0010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12066_bb0015","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1002\/rth2.12066_bb0020","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0025","first-page":"637","article-title":"Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange","volume":"2015","author":"Coppo","year":"2015","journal-title":"Hematology \/ the Education Program of the American Society of Hematology American Society of Hematology Education Program"},{"key":"10.1002\/rth2.12066_bb0030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first\u2010line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1002\/rth2.12066_bb0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/jth.13186","article-title":"High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence","volume":"14","author":"von Krogh","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12066_bb0040","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","article-title":"Unexpected frequency of Upshaw\u2010Schulman syndrome in pregnancy\u2010onset thrombotic thrombocytopenic purpura","volume":"119","author":"Moatti\u2010Cohen","year":"2012","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0045","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0050","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1055\/s-2005-925476","article-title":"Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease?","volume":"31","author":"Willis","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1002\/rth2.12066_bb0055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/(SICI)1098-1101(1998)13:3<133::AID-JCA7>3.0.CO;2-Z","article-title":"United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange","volume":"13","author":"Bandarenko","year":"1998","journal-title":"J Clin Apher"},{"key":"10.1002\/rth2.12066_bb0060","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7326\/0003-4819-122-8-199504150-00002","article-title":"Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura","volume":"122","author":"Shumak","year":"1995","journal-title":"Canadian Apheresis Group. Ann Intern Med"},{"key":"10.1002\/rth2.12066_bb0065","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00277-015-2411-2","article-title":"Headache prevalence following recovery from TTP and aHUS","volume":"94","author":"Saultz","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1002\/rth2.12066_bb0070","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1537-2995.2009.02101.x","article-title":"Cognitive deficits after recovery from thrombotic thrombocytopenic purpura","volume":"49","author":"Kennedy","year":"2009","journal-title":"Transfusion"},{"key":"10.1002\/rth2.12066_bb0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.21881","article-title":"Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura","volume":"86","author":"Cataland","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12066_bb0080","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long\u2010term follow\u2010up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0085","first-page":"21","article-title":"Hyaline thrombosis of the terminal arteriorles and capillaries: a hitherto undescribed disease","volume":"24","author":"Moschcowitz","year":"1924","journal-title":"Proc NY Pathol Soc"},{"key":"10.1002\/rth2.12066_bb0090","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura\u2010hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12066_bb0095","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12066_bb0100","unstructured":"Cataland S, Yang S, Masias C, et\u00a0al., eds. A Prospective, Randomized Study of Cyclosporine or Corticosteroids As an Adjunct to Plasma Exchange for the Treatment of Thrombotic Thrombocytopenic Purpura. American Society of Hematology 58th Annual Meeting and Exposition; 2016 Dec 3\u20106 2016, San Diego, CA."},{"key":"10.1002\/rth2.12066_bb0105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood-2010-11-317859","article-title":"Antithrombotic drug candidate ALX\u20100081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs","volume":"118","author":"Ulrichts","year":"2011","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0110","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2012-04-420943","article-title":"Evaluation of efficacy and safety of the anti\u2010VWF Nanobody ALX\u20100681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura","volume":"120","author":"Callewaert","year":"2012","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0115","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12066_bb0120","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"Peyvandi","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12066_bb0125","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1182\/blood-2002-05-1397","article-title":"Cloning, expression, and functional characterization of the von Willebrand factor\u2010cleaving protease (ADAMTS13)","volume":"100","author":"Plaimauer","year":"2002","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0130","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1365-2141.2003.04183.x","article-title":"ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor\u2010cleaving protease activity by recombinant human ADAMTS13","volume":"120","author":"Antoine","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1002\/rth2.12066_bb0135","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1182\/blood-2011-09-380535","article-title":"A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13","volume":"119","author":"Schiviz","year":"2012","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0140","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"A recombinant human ADAMTS\u201013: first\u2010in\u2010human study evaluating pharmacokinetics, safety and tolerability in cTTP patients","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0145","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","article-title":"Recombinant ADAMTS13 normalizes von Willebrand factor\u2010cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies","volume":"9","author":"Plaimauer","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12066_bb0150","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/ATVBAHA.115.306014","article-title":"Potential for Recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura","volume":"35","author":"Tersteeg","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1002\/rth2.12066_bb0155","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/jth.13137","article-title":"Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS\u201013 activity levels in inhibitor\u2010treated rats by the use of defined doses of recombinant ADAMTS\u201013","volume":"13","author":"Plaimauer","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12066_bb0160","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1172\/JCI41062","article-title":"N\u2010acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice","volume":"121","author":"Chen","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1002\/rth2.12066_bb0165","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2016-09-738856","article-title":"N\u2010acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura","volume":"129","author":"Tersteeg","year":"2017","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0170","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/trf.12440","article-title":"Treatment of refractory thrombotic thrombocytopenic purpura with N\u2010acetylcysteine: a case report","volume":"54","author":"Li","year":"2014","journal-title":"Transfusion"},{"key":"10.1002\/rth2.12066_bb0175","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s11239-015-1259-6","article-title":"The role of N\u2010acetylcysteine in the treatment of thrombotic thrombocytopenic purpura","volume":"41","author":"Rottenstreich","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1002\/rth2.12066_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215491","article-title":"Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura","author":"Acedillo","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1002\/rth2.12066_bb0185","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","article-title":"Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura","volume":"157","author":"Chapin","year":"2012","journal-title":"Br J Haemat"},{"key":"10.1002\/rth2.12066_bb0190","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1002\/rth2.12066_bb0195","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1160\/TH13-06-0490","article-title":"Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis","volume":"111","author":"Lei","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12066_bb0200","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/bloodadvances.2016000711","article-title":"Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura","volume":"1","author":"Zheng","year":"2016","journal-title":"Blood Adv"},{"key":"10.1002\/rth2.12066_bb0205","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12066_bb0210","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/trf.12614","article-title":"Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report","volume":"54","author":"Yates","year":"2014","journal-title":"Transfusion"},{"key":"10.1002\/rth2.12066_bb0215","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/bjh.12696","article-title":"Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura","volume":"164","author":"Mazepa","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1002\/rth2.12066_bb0220","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/ejh.12206","article-title":"Refractory thrombotic thrombocytopenic purpura in a 16\u2010year\u2010old girl: successful treatment with bortezomib","volume":"92","author":"Van Balen","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1002\/rth2.12066_bb0225","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/trf.13465","article-title":"Rituximab\u2010refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib","volume":"56","author":"Patel","year":"2016","journal-title":"Transfusion"},{"key":"10.1002\/rth2.12066_bb0230","first-page":"9681832","article-title":"Remission of severe, relapsed, and refractory TTP after multiple cycles of bortezomib","volume":"2017","author":"Pandey","year":"2017","journal-title":"Case Rep Hematol"},{"key":"10.1002\/rth2.12066_bb0235","doi-asserted-by":"crossref","first-page":"582","DOI":"10.7326\/0003-4819-47-3-582","article-title":"Thrombotic thrombocytopenic purpura (Moschcowitz's disease): report of a case with remission after splenectomy and steroid therapy","volume":"47","author":"Shapiro","year":"1957","journal-title":"Ann Intern Med"},{"key":"10.1002\/rth2.12066_bb0240","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood.V6.8.706.706","article-title":"Thrombotic thrombocytopenic purpura, a disseminated disease of arterioles","volume":"6","author":"Meacham","year":"1951","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0245","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF01784041","article-title":"The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura","volume":"70","author":"Veltman","year":"1995","journal-title":"Ann Hematol"},{"key":"10.1002\/rth2.12066_bb0250","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ajh.20678","article-title":"Outcomes in the treatment of thrombotic thrombocytopenic purpura with splenectomy: a retrospective cohort study","volume":"81","author":"Outschoorn","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12066_bb0255","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2005.05681.x","article-title":"Splenectomy for the treatment of thrombotic thrombocytopenic purpura","volume":"130","author":"Kappers\u2010Klunne","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1002\/rth2.12066_bb0260","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0265","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Page","year":"2016","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0270","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2014-04-561142","article-title":"The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen\u2010binding CDR3 motifs","volume":"124","author":"Schaller","year":"2014","journal-title":"Blood"},{"issue":"Supl S1","key":"10.1002\/rth2.12066_bb0275","first-page":"1295","article-title":"Splenic anti\u2010ADAMTS13 response in relapsing thrombotic thrombocytopenic purpura (iTTP) patients mirrors the acute immune response in plasma","volume":"124","author":"Skowronoska","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1002\/rth2.12066_bb0280","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ajh.10204","article-title":"Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab","volume":"71","author":"Chemnitz","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12066_bb0285","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1006\/bcmd.2002.0522","article-title":"Rituximab therapy for refractory thrombotic thrombocytopenic purpura","volume":"28","author":"Gutterman","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"10.1002\/rth2.12066_bb0290","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS\u201013","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"issue":"Suppl. S1","key":"10.1002\/rth2.12066_bb0295","first-page":"1297","article-title":"Retrospective analysis of the relapse rate in patients surviving acute acquired thrombotic thrombocytopenic purpura (TTP) treated with or without rituximab","volume":"1","author":"Herold","year":"2017","journal-title":"Res Pract Thromb Haemost."},{"key":"10.1002\/rth2.12066_bb0300","unstructured":"Mansouri M, Matsumoto M, Cermakova Z, Friedman KD, George JN, Hrachovinova I, et\u00a0al., editors. Hereditary TTP \u2013 a young patient population with high prevalence of arterial thromboembolic events: first results from the hereditary TTP registry. XXV Congress of the International Society on Thrombosis and Haemostasis; 2015; Toronto."},{"issue":"Suppl. 1","key":"10.1002\/rth2.12066_bb0305","first-page":"254","article-title":"Conformation of ADAMTS13 is Altered in Acquired TTP Patients","volume":"1","author":"Roose","year":"2017","journal-title":"Res Pract Thromb Haemost."},{"issue":"Suppl. S1","key":"10.1002\/rth2.12066_bb0310","first-page":"254","article-title":"Autoantibody binding to \u2018Open\u2019 and \u2018Closed\u2019 ADAMTS13 in patients with acquired immune thrombotic thrombocytopenic purpura","volume":"1","author":"Underwood","year":"2017","journal-title":"Res Pract Thromb Haemost."},{"issue":"Suppl. 1","key":"10.1002\/rth2.12066_bb0315","first-page":"254","article-title":"PAD4 Citrullination of ADAMTS13: a new link between NETosis and thrombosis","volume":"1","author":"Sorvillo","year":"2017","journal-title":"Res Pract Thromb Haemost."},{"key":"10.1002\/rth2.12066_bb0320","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2016-06-724161","article-title":"Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura","volume":"128","author":"Page","year":"2016","journal-title":"Blood"},{"key":"10.1002\/rth2.12066_bb0325","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2141.2008.07107.x","article-title":"Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse","volume":"141","author":"Jin","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1002\/rth2.12066_bb0330","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti\u2010ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12066_bb0335","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.113.006727","article-title":"Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy","volume":"129","author":"Tersteeg","year":"2014","journal-title":"Circulation"},{"key":"10.1002\/rth2.12066_bb0340","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/ATVBAHA.116.308524","article-title":"Plasmin cleaves von Willebrand factor at K1491\u2010R1492 in the A1\u2010A2 linker region in a shear\u2010 and glycan\u2010dependent manner in vitro","volume":"37","author":"Brophy","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl. S1","key":"10.1002\/rth2.12066_bb0345","first-page":"1293","article-title":"Plasmin cleavage of ADAMTS\u201013 enhances its Activity","volume":"1","author":"Mebius","year":"2017","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frth2.12066","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922016454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922016454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/rth2.12066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:17:14Z","timestamp":1762863434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922016454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S2475037922016454"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12066","relation":{},"ISSN":["2475-0379"],"issn-type":[{"type":"print","value":"2475-0379"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapies in thrombotic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}